Why I'm Not Buying Vaxart Stock
Vaxart (NASDAQ: VXRT) had an amazing run in 2020. The tiny biotech started off the year as a micro-cap stock, but when the COVID-19 pandemic struck, it -- like many vaccine-related stocks -- took off. Vaxart jumped out of obscurity and delivered one of the market's top performances of the year, rising by more than 1,530%.
Wall Street was particularly excited about Vaxart's coronavirus vaccine candidate, because it is delivered in the form of an oral tablet. All of the leaders in this vaccine race -- including those that have already crossed the finish line and earned approval -- are injections. So, the theory goes, if Vaxart's pill is successful, the company will have an opportunity to take a significant market share because pills are far more popular and easier to distribute than shots. Its pills can be stored at room temperature, giving them a big advantage over the COVID-19 vaccines being sent around the world right now. (The mRNA vaccines from Pfizer and Moderna must be shipped and stored at extremely cold temperatures.)
So there's a clear bull case for the stock. What about the bear case?
Source Fool.com
